Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Kasenda

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|January 12, 2019
CNS border posts against rituximab?Benjamin Kasenda, Gerald Illerhaus
Progress in Tumor Research|September 18, 2015
Immunotherapies in Early and Advanced Renal Cell CancerBenjamin Kasenda, James Larkin, Martin Gore
Blood|July 11, 2018
Novel agents for primary central nervous system lymphoma: evidence and perspectivesGerald Illerhaus, Elisabeth Schorb, Benjamin Kasenda
Expert Review of Hematology|November 20, 2015
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomasBenjamin Kasenda, Andrea Kühnl, Ian Chau
Swiss Medical Weekly|March 13, 2012
Meta-analyses: what they can and cannot doAlain J Nordmann, Benjamin Kasenda, Matthias Briel
Therapeutische Umschau. Revue Therapeutique|March 29, 2013
[Lung cancer screening - an overview about chances and risks]Benjamin Kasenda, Heike Raatz, Heiner C Bucher
Systematic Reviews|June 3, 2014
Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation--protocol of the ICEM studyBenjamin Kasenda, Willi Sauerbrei, Patrick Royston, et al.
The Cochrane Database of Systematic Reviews|June 17, 2014
The role of additional radiotherapy for primary central nervous system lymphomaJonas Zacher, Benjamin Kasenda, Andreas Engert, et al.
BMJ (Clinical Research Ed.)|July 12, 2018
How to use FDA drug approval documents for evidence synthesesAviv Ladanie, Hannah Ewald, Benjamin Kasenda, et al.
American Journal of Epidemiology|March 13, 2025
Association of cancer incidence and randomized trial evidence for FDA approval of new cancer drugsAndreas M Schmitt, Amanda Herbrand, Benjamin Kasenda, et al.
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|January 12, 2019
CNS border posts against rituximab?Benjamin Kasenda, Gerald Illerhaus
Progress in Tumor Research|September 18, 2015
Immunotherapies in Early and Advanced Renal Cell CancerBenjamin Kasenda, James Larkin, Martin Gore
Blood|July 11, 2018
Novel agents for primary central nervous system lymphoma: evidence and perspectivesGerald Illerhaus, Elisabeth Schorb, Benjamin Kasenda
Expert Review of Hematology|November 20, 2015
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomasBenjamin Kasenda, Andrea Kühnl, Ian Chau
Swiss Medical Weekly|March 13, 2012
Meta-analyses: what they can and cannot doAlain J Nordmann, Benjamin Kasenda, Matthias Briel
Therapeutische Umschau. Revue Therapeutique|March 29, 2013
[Lung cancer screening - an overview about chances and risks]Benjamin Kasenda, Heike Raatz, Heiner C Bucher
Systematic Reviews|June 3, 2014
Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation--protocol of the ICEM studyBenjamin Kasenda, Willi Sauerbrei, Patrick Royston, et al.
The Cochrane Database of Systematic Reviews|June 17, 2014
The role of additional radiotherapy for primary central nervous system lymphomaJonas Zacher, Benjamin Kasenda, Andreas Engert, et al.
BMJ (Clinical Research Ed.)|July 12, 2018
How to use FDA drug approval documents for evidence synthesesAviv Ladanie, Hannah Ewald, Benjamin Kasenda, et al.
American Journal of Epidemiology|March 13, 2025
Association of cancer incidence and randomized trial evidence for FDA approval of new cancer drugsAndreas M Schmitt, Amanda Herbrand, Benjamin Kasenda, et al.
Pageof 9